北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial
作者: Sima, L.1; Fang, W. X.2; Wu, X. M.3,4; Li, F.5
关键词: oxycodone ; pain ; paracetamol
刊名: JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
发表日期: 2012-02-01
DOI: 10.1111/j.1365-2710.2010.01239.x
卷: 37, 期:1, 页:27-31
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: CONTROLLED-RELEASE OXYCODONE ; NONSTEROIDAL ANTIINFLAMMATORY DRUGS ; NEUROPATHIC PAIN ; ACETAMINOPHEN ; MANAGEMENT
英文摘要:

What is known and Objective: Bone-cancer pain is a common and refractory cancer pain. Opioids, on their own, do not control this type of pain well enough, and co-analgesics are necessary.

Methods: Patients with bone metastasis-related pain at Numeric Rating Scale 4 were enrolled to this randomized placebo-controlled trial. They had also received morphine or transdermal fentanyl patches for at least 1 week. During the 3-day efficacy phase, patients received placebo or 1-3 tablets of oxycodone/paracetamol (5/325 mg), four times daily for 3 days. All patients kept a daily pain diary. The primary endpoint was the Pain Intensity Difference (PID). Secondary endpoints were cases of breakthrough pain and rescue morphine consumption. Additional analyses included the Short Form-6 Dimensions (SF-6D) quality-of-life scale and a general impression (GI) of patient satisfaction with treatment at the end of the phase.

Results and Discussion: Of the 246 patients in the intent-to-treat set, 89.4% completed the 3-day efficacy phase. PIDs were 0.9 and 0.3 in the oxycodone/paracetamol and placebo groups respectively, on day 1 (P < 0.001), and 1.5 and 0.3 respectively on day 3 (P < 0.001). Thirty-eight patients in the treatment group, and 58 in the placebo group, suffered breakthrough pain on day 3 (P < 0.001). The SF-6D score decreased to 21.2 +/- 2.5 in the oxycodone/paracetamol group at the end of the phase (P = 0.001). In the oxycodone/paracetamol group, 67% rated GI as good, very good, or excellent.

What is new and Conclusion: Patients with bone-cancer pain, already on opioids, obtain clinically important, additional pain-control, with regular oxycodone/paracetamol dosing.

语种: 英语
WOS记录号: WOS:000299549500005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/57058
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.China Japan Friendship Hosp, Natl Pain Management & Res Ctr, Beijing 100029, Peoples R China
2.Peking Univ, Dept Anesthesia, Hosp 1, Beijing 100871, Peoples R China
3.Chinese Acad Med Sci, Dept Polyclin, Canc Inst & Hosp, Beijing 100730, Peoples R China
4.Peking Union Med Coll, Beijing 100021, Peoples R China
5.Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China

Recommended Citation:
Sima, L.,Fang, W. X.,Wu, X. M.,et al. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS,2012,37(1):27-31.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sima, L.]'s Articles
[Fang, W. X.]'s Articles
[Wu, X. M.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sima, L.]‘s Articles
[Fang, W. X.]‘s Articles
[Wu, X. M.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace